Morepen Laboratories Overview

  • Founded
  • 1984

Founded
  • Status
  • Public

  • Employees
  • 1,510

Employees
  • Stock Symbol
  • 500288

Stock Symbol
  • Share Price
  • $0.44

  • (As of Monday Closing)

Morepen Laboratories General Information

Description

Morepen Laboratories Ltd is an India based pharmaceutical company. It develops, manufactures and markets generic drugs and pharmaceutical formulations. The company's products include Tablets, Capsules, Injections, Ointments, Syrups, and Powders. It also offers products under brands Burnol, Lemolate and Fiber-X. The company's geographical markets include India, the United States and the rest of the world, with a majority of revenue being generated in India.

Contact Information

Website
www.morepen.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Stock Exchange
BOM
Primary Office
  • 409, Antriksh Bhawan
  • 22 Kasturba Gandhi Marg
  • New Delhi, Delhi 110001
  • India
+91 098183 00000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Morepen Laboratories Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.44 $0.45 $0.41 - $0.84 $221M 499M 232K $0.02

Morepen Laboratories Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2022 31-Mar-2022 FY 2021 31-Mar-2021 FY 2020 31-Mar-2020
EV 240,501 225,195 189,805 54,994
Revenue 194,084 207,607 159,685 118,170
EBITDA 15,528 19,727 17,551 10,318
Net Income 10,197 13,647 13,049 4,726
Total Assets 141,115 116,841 87,969
Total Debt 0 2,449 2,321 1,786
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Morepen Laboratories Patents

Morepen Laboratories Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10626093-B2 Polymorphic form of crystalline rosuvastatin calcium and novel processes for crystalline as well as amorphous rosuvastatin calcium Active 18-Apr-2016 0000000000 0
US-20190127334-A1 New polymorphic form of crystalline rosuvastatin calcium & novel processes for crystalline as well as amorphous rosuvastatin calcium Granted 18-Apr-2016 0000000000
EP-3445751-A4 New polymorphic form of crystalline rosuvastatin calcium&novel processes for crystalline as well as amorphous rosuvastatin calcium Pending 18-Apr-2016 0000000000
EP-3445751-A1 New polymorphic form of crystalline rosuvastatin calcium&novel processes for crystalline as well as amorphous rosuvastatin calcium Pending 18-Apr-2016 0000000000
AU-2003253247-A1 An improved method for the preparation of montelukast acid and sodium salt thereof in amorphous form Abandoned 06-Jun-2003 C07D215/18
To view Morepen Laboratories’s complete patent history, request access »

Morepen Laboratories Executive Team (1)

Name Title Board Seat Contact Info
Varun Suri Chief Executive Officer
To view Morepen Laboratories’s complete executive team members history, request access »

Morepen Laboratories Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Morepen Laboratories Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Morepen Laboratories‘s full profile, request access.

Request a free trial